SystImmune, Inc.

SystImmune Inc. is a biopharmaceutical company focused on developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. Our objective is to create biologics that work through systematic intervention on tumor microenvironments, that directly attack the tumor and to activate the immune system to attack the tumor.



SystImmune-Inc is a US based enterprise company of the Sichuan Biokin Pharmaceutical Co., Ltd group. We are partnered with the venture capital firm OrbiMed and willing to seek parties interested in working with us to develop, commercialize, and bring our novel therapeutics to patients around the world.


Who We Are

We are a group of R&D and clinical scientists and biotech professionals utilizing several advanced technology platforms to develop world class antibody-based drug therapies. Our global clinical development strategy provides SystImmune’s drug programs multiple concurrent commercial opportunities that capitalize on US and Asia market efficiency.

Protein Engineering

Incorporation of binding domains into proprietary multi-specific antibody and ADC platforms, optimization of antibody properties such as humanness, stability, and binding and generation of high-quality antigen for a tailored antibody response.  

Antibody Development

Identification of monoclonal antibodies from rabbit and alpaca using B cell enrichment and sorting, or yeast display strategies enable selection of core assets with unique characteristics defined by screening using novel miniaturized immuno-assays.

Process Development

Integrated and efficient titer optimizing CHO production platforms provide the foundation of our Downstream, Upstream, Formulation, and Analytical Group capability to manufacture our biotherapeutics.


Founded Redmond, WA


Active Clinical Trials


Most Advanced Trial Stage


Firsts in Cancer Biologics Development

ongoing development

What's Next

As a clinical stage biotech company, SystImmune continues its highly active R&D programs. To produce future generations of breakthrough therapeutics from the Pacific North West.

"SystImmune is committed to improving the health and quality of life of cancer patients. As we work together to develop new therapeutics, I feel the original vision of SystImmune is alive as we aim high with novel breakthrough therapeutics designs."

Dr. Yi Zhu

President & CEO

Ready to get started?